Boehringer Ingelheim Group of companies
In 2009, Boehringer Ingelheim again posted gratifying growth over the previous year.
Financial Highlights 2009
| 2009
|
2008
|
Change
|
|
|---|---|---|---|
| Net sales
|
12,721
|
11,595
|
+10 %
|
| Net sales by region
|
|||
| Europe
|
31 %
|
33 %
|
|
| Americas
|
49 %
|
48 %
|
|
| Asia, Australasia, Africa
|
20 %
|
19 %
|
|
|
Net sales by business area |
|||
| Human Pharmaceuticals
|
95 %
|
96 %
|
|
| Animal Health
|
5 %
|
4 %
|
|
| Research and Development
|
2,215
|
2,109
|
+5 %
|
| Personnel costs
|
3,221 | 3,004
|
+7 %
|
| Average number of employees
|
41,534
|
41,300
|
+1 %
|
| Operating income
|
2,239
|
1,980
|
+13 %
|
| Operating income as % of sales
|
17.6 %
|
17.1 %
|
|
| Income after taxes
|
1,764
|
1,428
|
+24 %
|
| Income after taxes as % of sales
|
13.9 %
|
12.3 %
|
|
| Shareholders' equity
|
5,901
|
4,703
|
+25 %
|
| Return on shareholders' equity
|
37.4 %
|
42.2 %
|
|
| Cash Flow
|
2,409
|
1,997
|
+21 %
|
| Investments in tangible assets
|
630
|
665
|
-5 %
|
| Depreciation of tangible assets
|
470
|
453
|
+4 % |
